Glial Fibrillary Acidic Protein (GFAP) is a type III intermediate filament protein primarily expressed in astrocytes and represents one of the most important biomarkers for astroglial activation and neurodegeneration[1]. First discovered in the 1970s, GFAP has become a cornerstone in the study of neuroinflammation and astrocyte involvement in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and multiple system atrophy (MSA)[2].
The protein serves dual roles: as a structural component of the astrocytic cytoskeleton and as a released biomarker that can be measured in cerebrospinal fluid (CSF) and blood. GFAP levels reflect astrocyte reactivity, blood-brain barrier integrity, and the extent of neuroinflammation in various neurological conditions[3].
| Property | Value |
|---|---|
| Full Name | Glial Fibrillary Acidic Protein |
| Gene Symbol | GFAP |
| UniProt ID | P14136 |
| Chromosomal Location | 17q21.31 |
| Molecular Weight | ~50 kDa |
| Protein Family | Type III intermediate filament |
| Primary Expression | Astrocytes, neural stem cells, ependymal cells |
| Sample Types | CSF, Blood (plasma/serum) |
| Assay Methods | Simoa, ELISA, Western Blot |
The GFAP gene spans approximately 10 kb on chromosome 17q21.31 and consists of 9 coding exons. The gene produces multiple splice variants through alternative splicing of exons 7 and 8, generating protein isoforms of varying molecular weights (40-50 kDa)[4]. Expression is regulated by several transcription factors including:
GFAP possesses a central alpha-helical rod domain flanked by non-alpha-helical head and tail regions. The protein assembles into homodimers that further form tetramers and higher-order filaments. This structure provides:
GFAP undergoes extensive post-translational modifications that modulate its function:
GFAP has emerged as a powerful biomarker for Alzheimer's disease, reflecting the prominent astrocytic pathology present in AD brains[5]. Key applications include:
Diagnostic Value
Disease Progression
Pathophysiological Context
In Parkinson's disease, GFAP serves as a marker of astrocyte involvement in dopaminergic neuron degeneration[9]:
Differential Diagnosis
GFAP is a valuable biomarker in ALS, reflecting the pronounced astrocytic pathology that characterizes this progressive neurodegenerative disease[11]:
CSF GFAP in ALS
Blood GFAP in ALS
Combination Biomarkers
GFAP shows distinct patterns in MSA, a neurodegenerative disorder affecting autonomic neurons and cerebellar/basal ganglia structures[10:1]:
In PSP, GFAP levels reflect the prominent astrocytic pathology (thorn-shaped astrocytes) characteristic of this 4R tauopathy[12]:
GFAP helps differentiate DLB from AD, as astroglial responses differ between these conditions[13]:
CSF GFAP measurement represents the gold standard for neurological assessment:
Blood GFAP offers less invasive sampling with good correlation to CSF levels[14]:
Simoa (Single Molecule Array)
ELISA
Correlation: CSF and blood levels show good correlation (r = 0.7-0.9)
| Population | Mean (ng/mL) | Range (ng/mL) |
|---|---|---|
| Healthy Controls | 15-20 | 10-30 |
| Mild Cognitive Impairment | 25-35 | 15-50 |
| Alzheimer's Disease | 40-60 | 20-100 |
| Parkinson's Disease | 25-40 | 15-60 |
| Multiple System Atrophy | 50-80 | 30-120 |
| ALS | 45-70 | 25-110 |
| PSP | 35-55 | 20-80 |
| Population | Mean (pg/mL) | Range (pg/mL) |
|---|---|---|
| Healthy Controls | 80-120 | 40-200 |
| MCI | 150-200 | 80-350 |
| Alzheimer's Disease | 200-300 | 100-500 |
| Parkinson's Disease | 120-180 | 60-300 |
For clinical decision-making, typical cutoffs are set at:
GFAP performs best in combination with other biomarkers:
| Combination | AUC (AD vs Controls) | Primary Use |
|---|---|---|
| GFAP + p-tau181 | 0.88-0.92 | Early AD detection |
| GFAP + NfL | 0.85-0.90 | Disease progression |
| GFAP + Aβ42/40 | 0.90-0.95 | Preclinical screening |
| GFAP + p-tau + NfL | 0.93-0.97 | Comprehensive panel |
| GFAP + α-synuclein | 0.82-0.88 | Synucleinopathy differentiation |
The GFAP gene contains several polymorphisms associated with:
GFAP expression is regulated by:
Petzold A, et al. GFAP: a biomarker for astrocyte dysfunction in neurological disorders. Lancet Neurology. 2007. ↩︎
Elobeid A, et al. GFAP in Alzheimer disease: a systematic review and meta-analysis. Experimental Neurology. 2016. ↩︎ ↩︎
Khalil M, et al. Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology. 2018. ↩︎ ↩︎
Jung HI, et al. GFAP isoforms in neurodegenerative disease. Molecular Neurodegeneration. 2022. ↩︎ ↩︎
Pereira JB, et al. Plasma GFAP detects tauopathy and predicts cognitive decline. Nature Medicine. 2023. ↩︎
Barro C, et al. GFAP as a biomarker for disease progression in MS and AD. Annals of Neurology. 2020. ↩︎
Askenholt M, et al. Blood GFAP predicts progression in Alzheimer's disease. Alzheimer's & Dementia. 2023. ↩︎
Kawasaki Y, et al. GFAP and NFL combination improves AD diagnosis. Alzheimer's & Dementia. 2024. ↩︎
Lipari L, et al. GFAP in Parkinson's disease: a meta-analysis. Journal of Neurology. 2023. ↩︎
Liu Y, et al. GFAP in multiple system atrophy: diagnostic value. Movement Disorders. 2023. ↩︎ ↩︎
Geloso MC, et al. Astrocytes in ALS: GFAP-mediated mechanisms. Neurobiology of Disease. 2023. ↩︎
Nakamura K, et al. GFAP in progressive supranuclear palsy. Journal of Neurology, Neurosurgery & Psychiatry. 2023. ↩︎
O'Sullivan M, et al. CSF GFAP differentiates dementia with Lewy bodies from AD. Neurology. 2022. ↩︎
Quinlan P, et al. Plasma GFAP in preclinical AD: biomarker performance. JAMA Neurology. 2023. ↩︎
Moreno M, et al. Longitudinal GFAP changes predict cognitive decline in MCI. Brain Communications. 2024. ↩︎
Czech C, et al. Astrocytic GFAP as a therapeutic target in AD. Acta Neuropathologica. 2024. ↩︎